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Human Papillomavirus (HPV) infection has been linked with cervical cancer. Some medical professionals see
it as the determining causal agent and therefore promote vaccination as an effective prevention strategy.
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The pathogenesis of Human Papillomavirus (HPV) in the development of cervical 
cancer: are HPV vaccines a safe and effective management strategy?   
Judy Wilyman MSc
Abstract
Human Papillomavirus (HPV) infection has been linked with cervical cancer. Some medical professionals 
see it as the determining causal agent and therefore promote vaccination as an effective prevention 
strategy. However, the biological plausibility of a causal theory requires that the incidence of the 
causal agent varies with the incidence and mortality of the disease. Yet the incidence and mortality of 
cervical cancer  do not vary with the incidence of infection with HPV strains 16 and 18; the strains 
covered by the HPV vaccine. Though HPV  infection is a necessary precursor to most cervical cancer, 
most high-risk HPV  infections (with one of 15 or more high–risk strains) do not progress to cervical 
cancer and HPV infection with any strain is not sufficient on its own to induce cervical cancer.  This 
evidence supports the conclusion that environmental and lifestyle factors are a determining cause in 
conjunction with HPV in the progression to cervical cancer. 
Clinical trials for the HPV vaccine did not attempt to observe the vaccine preventing any cervical 
cancer. Instead the trials looked for  pre-cancerous lesions in women 16 – 26 years of age. This was an 
inadequate surrogate for cervical cancer  because studies show that most lesions in this demographic 
clear  quickly without requiring treatment. Preventing infection from HPV  strains 16 and 18 also 
assumes these women will not get cervical cancer  from infection with one of the many other high risk 
strains that are prevalent. Therefore the decision to use an HPV  vaccine to prevent cervical cancer was 
based upon circumstantial evidence: assumptions. HPV  vaccines have been promoted to women on 
selective information. This vaccine is an HPV vaccine not a cervical cancer vaccine. There is 
inconclusive evidence it will reduce any cervical cancer and the long –term risks of using this vaccine 
have not been determined.  
Background
Cervical cancer has been studied worldwide for a century and a half and during this time many lifestyle 
and environmental factors have been implicated in its etiology 1. However, by 1995 the discovery of 
new hybridization technology led Bosch et al to claim “infection with HPV 16 and 18 is predictive of 
carcinoma and independent of other  factors” 2. In 2006, Munoz et al declared human papillomavirus 
(HPV) Type 16 and 18 to be the determining cause of cervical cancer 3.  These researchers stated “the 
causal role of human papillomavirus in all cancers of the uterine cervix has been firmly established 
biologically and epidemiologically” 3. This led to the release of a new vaccine to prevent HPV infection 
in the same year. It was promoted to the public as a vaccine that prevents cervical cancer 4, 5.   
At this time it was known that HPV infection on its own was not sufficient to cause cervical cancer 1, 6, 
7. Several co-factors had been identified as necessary for  the progression of normal epithelial cells to 
carcinoma. Whilst there is still doubt about the identity of some co-factors, those that are confirmed 
are: multiple partners for the male and female, presence of HPV plus other viruses (for example HPV  + 
Herpes Simplex Virus Type 2), prostitution, sex without a condom/microbicides, low socioeconomic 
status (poor  hygiene/sanitation/nutrition conducive to sexually transmitted diseases), 
immunosuppression, smoking, oral contraceptives 1, 6, 7. 
In addition, the plausibility of a causal theory, such as that put forward by Bosch et al, requires that 
the incidence and mortality of a disease varies with the factors implicated in the cause of the disease 
8. It also requires evidence that the disease develops only in cases where the virus is present 8. The 
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strongest evidence for proving that HPV 16 and 18 are the central etiological factors in cervical cancer 
worldwide would be a correlation between the incidence of HPV 16/18 worldwide and the incidence 
and mortality of cervical cancer worldwide 8. This evidence would be strengthened by performing long-
term prospective studies investigating biological and environmental factors that might operate in 
conjunction with HPV infection and would provide empirical evidence of the cause of cervical cancer 8. 
This is because these studies would include the correct follow up period or latent period between the 
initiation of the cancer and its development many years later 8, 9. In the case of cervical cancer this 
period has been estimated at about ten to twenty-five years 4, 9, 10. 
However, long-term prospective studies to determine the causality of cervical cancer have not been 
done 11. The pharmaceutical companies (manufacturers of the vaccine) that sponsored the trials for 
HPV vaccines decided long-term studies would be too costly due to the latent nature of the disease 11. 
In 1995 it was claimed that HPV DNA could be found in the majority of carcinomas 2. Prior  to 1995 the 
detection of HPV  DNA in different tissues had been unreliable and the sensitivity of the results varied 
with different technology 12. However, in 1995, it was being claimed that ‘new molecular biology 
techniques were truly sensitive and specific’ 13. 
These new techniques were used to re-analyse the Bosch et al, study that claimed 93% of tumors 
contained HPV  DNA 14. As a result it was concluded that 99.7% of tumors contained HPV DNA 14. In 
other words, the basis for  the claim that HPV is found in the majority of carcinomas was founded on a 
new technique for detecting HPV DNA that was promoted as being ‘truly sensitive and specific’.    
In 2003, it was stated that the role of HPV infection in the cause of cervical cancer was established and 
the World Health Organisation (WHO) was encouraged to test HPV vaccines as a preventative for 
cervical cancer; but not by observing actual cases of the disease 11. It was decided that a surrogate for 
cervical cancer  would be appropriate 11. The clinical trials for  the vaccine used the occurrence of pre-
cancerous lesions in women 16 -26 years of age as the end-point for  cervical cancer. This end-point was 
used as a surrogate for  proving the efficacy of the vaccine against cervical cancer in an age-group that 
rarely gets cervical cancer 4, 11.   
So despite evidence that co-factors are required for  the progression of normal cells to cancer  and 
despite a lack of definitive evidence supporting the claim that HPV 16/18 are necessary and sufficient 
to cause cancer, the HPV vaccine was promoted to all women as an effective preventative method.  In 
the following sections the validity of the claims that have been made about HPV vaccines are examined 
from an historical perspective of etiology.
The Incidence of HPV Worldwide
There are over 100 HPV sub-types that have been identified and 40 of these are known to infect the 
genital tract 3. Most strains of HPV  are common and harmless, however there are at least 20 types 
associated with cervical cancer: 14 of these are considered carcinogenic and these include HPV   -16, 
-18, -31, -33, -35, -39, -45, -51, -56, -58, -52, -26, -53, -66 2. These types are frequently found in 
cervical cancer  and are classified as ‘high-risk’ HPV’s 2. Other types such as HPV -6, -11, -42, -43 and 
-44 are rarely associated with cervical tumors and they are classified as low risk HPV types 2 .
High rates of genital HPV  infection are sustained in all communities throughout the world even in 
groups that do not have a high partner exchange 6. As there are striking differences in the rate of 
cervical cancer  globally, it has been postulated that the more ‘high-risk’ HPV types may be associated 
with higher rates of cervical cancer 6. The prevalence of HPV sub-types varies between communities 
but the prevalence of HPV 16 and 18 does not correlate to regions with a high risk for  cervical cancer 
15. High-risk sub-types are found in both developed and developing countries yet women in developing 
countries have a much greater risk of cervical cancer than woman in developed countries 16.  
Some similarities in the distribution of HPV  sub-types have been found in invasive cervical carcinomas 
across regions 17. HPV  16 was found to be the dominant strain in all countries (51% of cases) and HPV 
18 found consistently in 10-14% of cases 17. This led Clifford et al to claim that HPV 16 and 18 are 
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found in approximately 70% of all ICC cases 17. Trends were also noticed in the prevalence of other 
strains 2, 17. 
Figure 1 illustrates a summary of the trends observed in the distribution of HPV  sub-types in carcinomas 
globally:
Figure  1: HPV type-specific prevalence by Geographic Region. Bosch FX, Manos  M, Munoz N, Sherman M, 
Jansen A, Peto J, Schiffman  M, Moreno V, Kurman R, Shah K, International Biological Study on  Cervical 
Cancer (IBSCC), 1995, Prevalence of Human  Papillomavirus  in  Cervical Cancer: a Worldwide Perspective, 
Journal of the National Cancer Institute, Vol.87, No.11 
The study by Clifford et al claimed two thirds of ICC was associated with HPV 16 and 18, yet these two 
strains are not more prevalent in developing countries where the incidence of cervical cancer  is highest 
17. The prevalence of HPV  16 was higher  in America, Australia and Europe: the developed countries 
where the risk of cervical cancer is considered to be low 16. More than 16 high-risk HPV  sub-types are 
prevalent in all countries both in regions where the rates of cervical cancer are considered high and 
where they are considered low 17. These sub-types include 45, 31, 33, 58, 39, 59 and 52 2, 17. This 
trend can be observed in Figure 1.
Clifford et al state that heterogeneity in the distribution of high-risk HPV  subtypes in different 
populations should be taken into account when developing screening tests and predicting the effect of 
vaccines on the incidence of HPV infection 15.  The observed distribution of high-risk HPV sub-types led 
Clifford et al to conclude a vaccine against HPV  16 and 18 may prevent a larger proportion of ICC in the 
developed countries than in the developing countries 17. If this vaccine does not target the burden of 
cervical cancer  in the developing countries then it cannot claim to protect the population against 70% 
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of cervical cancer. This statement was made the year before the vaccine was introduced into 
developed nations and indicates there was no certainty of the effectiveness of this vaccine against 
cervical cancer. 
In addition, the claim by Clifford et al that HPV 16 and 18 are present in approximately 70% of ICC 
cases needs to be examined with respect to the limitations of the study. The cases included in this 
analysis were not representative of the burden of ICC worldwide 17. The study was under-represented 
by cases from Africa and Asia which together represent 64% of cervical cancer  cases and over-
represented by cases from Europe and North Africa that represent 20% of cervical cancer 17.   
Another  factor  which puts doubt on this claim is the variation in the methods used to detect HPV  in the 
different studies that were included in the meta-analysis. The Clifford et al study combined the results 
of 85 studies that used only Polymerase Chain Reaction (PCR) -based assays to identify HPV  DNA 17. 
However, not all PCR primer  sets enhance HPV sub-types with the same sensitivity and this puts 
uncertainty on the validity of the results of the meta-analysis 17. 
An example of the variation in results obtained by using different PCR assays was the Bosch et al 1995 
study. This study used MY09/11 polymerase chain reaction assay to detect HPV in 1000 tumors 2. HPV 
was found to be prevalent in 93% of the tumors using this technique 2. However, when a different 
detection method was applied it was found that HPV  was prevalent in 99.7% of cervical carcinomas 14. 
This allowed the researchers to conclude ‘a virtual absence of HPV-negative cancers (in 1000 tumors) 
implies that effective prophylactic vaccination might eliminate cervical cancer  worldwide’: even 
though the 1000 cases were not representative of the global risk of cervical cancer  14.  Appendix 1. 
This claim led to the trial of an HPV vaccine to prevent cervical cancer even though the International 
Agency for Research on Cancer (IARC) states case series can only provide suggestive results and can 
never serve as a basis for causal inferences 6.     
The Correlation between the Risk of HPV Infection and the Risk of Cervical Cancer Worldwide 
The incidence of HPV  infection in women worldwide is approximately 80 %, vastly greater  than the 
incidence of cervical cancer 16. The lifetime risk of cervical cancer  before the age of 64 is 0.8 % in a 
developed country and 1.5% in a developing country 16.  
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Figure  2: Incidence of Cervical Cancer Worldwide. Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global 
Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108
In developed countries the risk of cervical cancer  is considered very low 16. For example, in Australia 
the incidence of cervical cancer is 6.9 /100,000 women and the death rate is 1.9/100,000 women 11. 
Australia has one of the lowest rates of incidence and mortality from cervical cancer in the world: 99% 
of Australian women will not be affected by cervical cancer  in their  lifetime 11. In Australia, indigenous 
women have twice the risk of developing cervical cancer and the mortality rate is four  times that of 
non-indigenous women 11. In general Aboriginal communities in Australia are poorer communities and a 
high incidence of cervical cancer is associated with these conditions 18. This variation of risk between 
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indigenous and non-indigenous women indicates the significance of environmental and lifestyle factors 
in the etiology of this disease.
In contrast, the risk of cervical cancer in developing countries is considered to be high 16. In the 60’s 
and 70’s, developed countries had similar  rates of cervical cancer  to developing countries today 16. 
China has also seen a dramatic decline in the incidence of cervical cancer from 17.8 per  100,000 
women in 1985 to 6.8 in 2002 16. Developed countries have had improved living standards and greater 
access to screening programs and condoms since the 1960’s. In addition, the incidence of HPV infection 
is similar between all countries but the incidence of cervical cancer  is not 6. This also supports the 
theory that lifestyle and environmental risk factors act in conjunction with HPV infection to cause 
cervical cancer. 
 It should be noted that the mortality rates for cervical cancer are lower than incidence rates 16. 
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Figure  3: Mortality Rates for  Cervical Cancer  Worldwide. Parkin  DM, Bray F, Ferlay J, Pisani P, 2005, Global 
Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108
A comparison of the incidence and mortality rates for  cervical cancer  between countries is illustrated 
in Figure 4 (below). This graph shows that mortality rates are lower  than incidence rates for  cervical 
cancer and this disease is a much higher  risk in developing countries than developed countries. The 
difference in the risk of cervical cancer between countries has not been emphasised to women in the 
education campaigns for this disease. 
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Figure  4:  Age-standardized Incidence and Mortality Rates for  Cervix Uteri Cancer. Parkin  DM, Bray F, Ferlay J, 
Pisani P, 2005, Global Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108
Analysis of the evidence for HPV as the determining cause of cervical cancer 
HPV are a group of viruses with strong epitheliotrophic properties; that is, they have a strong affinity 
for epithelial cells 19. Epithelial cells normally harbor the virus and 80% of women are infected with 
HPV during their lifetime 19. Therefore a significant association between HPV and invasive cervical 
cancer (ICC) is expected 19. In 1989 it was unclear whether HPV was a passenger virus in carcinoma 
development or  whether  it played a causal role in the progression to ICC 19. The overall evidence in 
1989 pointed to a multi-factorial cause of cervical cancer as other  determinants consistently emerged 
as independent risk factors in epidemiological investigations 20.
The conclusion that HPV is the determining causal factor in cervical cancer development has been 
based upon the research by Bosch et al investigating the worldwide prevalence of HPV  in 1000 cervical 
cancer tumors 2. 
Epidemiologists claim there is a “highly statistically significant association between HPV and the 
development of cervical intraepithelial neoplasia (CIN) grade 2 or 3 with persistent CIN 2/3 and with 
development of cervical cancer” 1. Carcinogenicity of HPV 16 and 18 is supported by experimental 
evidence that proteins of these viruses interfere with the functions of cellular  regulatory pathways 6. 
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However, Walboomers et al state “whilst persisting infection of the cervix with high-risk HPV is 
necessary for the development of cervical cancer, it is certainly not sufficient” 14.
There would be strong evidence for HPV  as the main independent cause of cervical cancer if the 
majority of cases of infection with HPV 16 and 18 progressed to cervical cancer. But they do not. The 
Australian Government states cervical cancer is a rare outcome of high-risk HPV infection and this is 
supported by the International Agency for  Research on Cancer  (IARC) 6, 7. In addition, it would be 
expected that the incidence and mortality of cervical cancer  would vary with the incidence of HPV 16 
and 18 across the globe if these strains are the determining cause of most cervical cancer. We have 
already observed that there is no correlation between the incidence of cervical cancer and incidence 
of high-risk HPV sub-types, including HPV  16/18, so it is necessary to examine the influence of lifestyle 
and environmental factors as co-factors in cancer development.
The Evidence for an Etiological Association with Environmental and Lifestyle factors
For  many decades public health scientists have used the epidemiological triangle, consisting of host, 
agent and environment, to assist in determining the etiology of infectious disease 8. This model of 
causality has been revered as “one of the fundamental public health concepts of disease causality and 
well suited to determining the cause of infectious diseases” 8.
Whilst an agent must be present for an infection to occur, other factors, such as the characteristics of 
the environment and the host, also play a role in determining whether events progress to an active 
case of the disease 8.  This public health fact and the evidence cited here show that the claim by Bosh 
et al (1995) that “infection with HPV 16 and 18 is predictive of carcinoma and independent of other 
factors” is false 2. Evidence for this conclusion is summarised below:
1. HPV infection with any strain is not sufficient to cause cervical cancer 7.
2. Approximately eighty percent of women are infected with HPV yet ninety percent of these HPV 
infections do not lead to cancer or warts 6, 7.  
3. HPV 16 is identified as the pre-dominant sub-type in all countries yet cervical cancer  rates vary 
significantly between countries 16.  
4. Developed countries had the same high rates of cervical cancer  in the sixties and seventies as the 
developing countries today but this was reduced by changes in environmental and lifestyle factors 
and the introduction of screening 16.
5. There is an increased risk of cervical cancer with an increased number of sexual partners 6. 
6. Prostitutes have a four times greater  chance of getting cervical cancer even though the detection 
of HPV sub-types is similar to controls 21.
7. Condoms can reduce the risk of cervical cancer four-fold 9.
8. China had a high rate of cervical cancer  in 1985 but this was reduced to a low rate by 2002 
without the use of a vaccine 16.
9. Bosch et al highlight that the sensitivity of new molecular biology techniques confirm the 
plausibility of HPV infection as the pre-cursor  event leading to cervical cancer  2. However, a pre-
cursor event is not predictive of cancer if the majority of cases do not progress to cancer. 
10.Some scientists still claim 5-10% of tumors are not associated with any HPV DNA 1, 22. 
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11.It is postulated that HPV  16 and 18 are present in possibly 70% of tumors but it has not been 
proven 15. This statistic is dependent upon the detection methods used and still leaves 30% of 
cervical cancer unprotected by the vaccine. 
The use of Pre-cancerous Lesions in the Determination of Efficacy for the Vaccine
The WHO consultation group used four key features to suggest that observing the frequency of pre-
cancerous lesions (the virological endpoint of persistent HPV infection) in young women was a useful 
endpoint for testing a vaccine against cervical cancer 11. These features were:  
1. They are obligate precursors of cervical cancer
2. They are closely associated in temporal sequence to the development of invasive cervical 
cancer
3. They are associated with a high risk of development of invasive cervical cancer (ICC)
4. Reductions in incidence or treatment are shown to result in a reduction in risk of invasive 
cervical cancer.
The first three statements above are only true when the environmental and lifestyle risk factors (listed 
above) are also present 1, 6, 7. Yet the clinical trials for this vaccine did not select participants for 
these risk factors 23. The fourth statement needs to be qualified because cervical cancer  is a rare 
outcome of high-risk HPV  infection and there are many high-risk subtypes 6, 7. There is no evidence 
that just targeting HPV  16/18 will result in a significant reduction in the risk of cervical cancer. In 
order to suggest that this vaccine will be effective in reducing the burden of cervical cancer, it must be 
demonstrated that there is a correlation between the worldwide incidence of HPV 16 and 18 and 
mortality from cervical cancer. This has not been demonstrated.
Pre-cancerous lesions were chosen as the end-point for cervical cancer based upon two assumptions 11: 
1. The first assumption is that pre-cancerous lesions in this age group most often lead to cancer 
23. This assumption is incorrect. Pre-cancerous lesions in this age group are most often cleared 
quickly by the immune system 7, 10. It is also known that pre-cancerous lesions can persist for 
a lifetime without giving rise to cervical cancer 7.
2. The second assumption underpinning these clinical trials is that preventing strains 16 and 18 
from infecting women will prevent some cervical cancer. However, the prevention of strains 16 
and 18 from infecting provides an opportunity for  one of the many other high-risk HPV types to 
infect; there are about 20 of these 6. The Australian health department confirms that resolved 
infection with a high-risk HPV does not protect against other high-risk types 7. 
The two assumptions described above confirm that using the occurrence of pre-cancerous lesions, in 16 
-26 year olds, was an inappropriate end-point for  cervical cancer  development. This is because the 
relationship between HPV infection at a young age and development of cervical cancer  20 to 40 years 
later  is unknown 24. In addition, the fact that HPV of all sub-types is found in high frequency among 
women with normal cervices indicates that on its own HPV is not predictive of cancer 15. 
Ninety percent of HPV  infections have no clinical consequences at all: there is no development of 
genital warts or  progression to cervical cancer 6, 7. In 1990, Pfister noted ‘no papillomavirus is able to 
induce cancer right away and fully on its own’ (p.6, 12). Carcinomas usually develop only after primary 
lesions persist for  several months/years, which indicates that additional events are needed to trigger 
malignant growth 12. 
BSEM March 2011
The Health Hazards of Disease Prevention
8
Efficacy of the HPV Vaccine
The trials investigating the efficacy of HPV 16/18 vaccine in preventing cervical cancer  observed that 
women, 16-26 years old, who were given the vaccine, had fewer  pre-cancerous lesions than women 
who were not given the vaccine 23. However, this result was dependent upon the protocol of the study 
group 23. A significant reduction in pre-cancerous lesions was only observed in the study group that had 
not been infected with HPV 16/18 at baseline 23. 
The health department states that the HPV  vaccine does not prevent HPV infection (16 and 18) which 
was already present at the time of vaccination 7. The trials demonstrated only 44% efficacy in the 
study group that was infected with HPV  16/18 at baseline 25. Previous sexual activity is the main 
reason for  infection with HPV  7. In other  words, you are still susceptible to cervical cancer  if you were 
infected with HPV  16/18 prior to vaccination. This would be a large percentage of the population if 
HPV 16/18 are the dominant sub-types, as scientists are claiming.
Since the vaccine was marketed in 2006 there has been no screening for  HPV sub-types prior to 
vaccination so there is no conclusive data on the effectiveness of this HPV vaccine in preventing pre-
cancerous lesions in a demographic that rarely gets cervical cancer. Currently the only clinical trials 
that have been performed for this vaccine were funded by the manufacturers of the vaccine 23.   
The manufacturer of HPV vaccines claims the drug prevents “high-grade disease” based on its ability to 
prevent pre-cancerous lesions in women 16-26 years of age 23. High-grade disease was measured by the 
presence of pre-cancerous lesions that were graded CIN 2 or  3 10, 23. These types of lesions were 
thought to be the immediate precursors of cervical cancer when the trials were performed in 
2000-2004 23. However, new guidelines regarding the natural history of cervical cancer  were 
introduced in Australia in 2005 which indicated scientists no longer believed this to be the case 7.  
Previously, the guidelines for the treatment of cervical cancer  implied a progression from CIN 1, CIN 2 
and CIN 3 to cancer  7.  The new belief is that “rather than an inevitable linear progression towards 
cancer, most precursor HPV infections (CIN 2 and 3) acquired by women resolve without medical 
intervention” 7. 
If CIN 3 does change into invasive cancer  the time frame for  this to happen averages between 8.1 to 
12.6 years 10. Yet the longest follow up study of the HPV vaccine during the clinical trials was only 4 
years 10, 23. In addition, “the vast majority of women (16-26 years of age) clear or  suppress HPV  to 
levels not associated with CIN 2 or 3 (high-grade disease) and for most women this occurs promptly” 
10.  Raffle et al state that modeling data from the United Kingdom suggests that eighty percent of 
high-grade intraepithelial abnormalities will regress without intervention (as cited in 7).
Therefore, the correct assumption is that pre-cancerous lesions in this age-group are not an indication 
that cervical cancer will develop from a high –risk HPV infection. The clinical trials do not provide 
conclusive evidence that a reduced number of pre-cancerous lesions in women 16-26 years of age (even 
if not previously infected with HPV  16/18) will reduce the incidence of cervical cancer  in older women: 
the age groups with the highest incidence of cervical cancer. The only conclusive evidence obtained 
from the clinical trials in this age group was that the drug prevents infection from two out of many 
strains of high-risk HPV’s identified in cervical cancer cases. It was assumed that fewer pre-cancerous 
lesions in the vaccinated group indicated a reduction in cervical cancer cases in older women, but the 
evidence discussed above suggests otherwise. 
Promotion of Benefits and Risks of the Vaccine
In 2006 when the HPV vaccine was licensed and marketed to females, the phase 3 clinical trials had 
not been completed 25. In other  words, the benefit and duration of this vaccine against cervical 
cancer had not been established. The promotional campaigns for this vaccine were funded by the 
vaccine manufacturer  and promoted through professional medical associations in America 26. This 
arrangement was established to ensure that the public received education about this vaccine from a 
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trusted source 26. The pharmaceutical companies supplied the medical associations with ready-made 
presentations and letters to promote Gardasil® as a preventative for  cervical cancer: even though the 
data was incomplete and it was primarily a guard against HPV viruses 25. Much of the promotional 
material did not address the complexity of the issues surrounding the vaccine and did not provide 
balanced advice regarding the risks and benefits of the vaccine 26. 
By promoting the vaccine as a preventative for  cancer, instead of a sexually transmitted infectious 
disease, the HPV vaccine was placed in the non-communicable disease category thus enabling the 
manufacturer to avoid public health officials who would have scrutinized a high-risk vaccination 
campaign 26. In addition, a law was passed in the United States in 1986 that permits vaccine 
manufacturers the right not to disclose known risks of vaccines to parents and guardians 27. It states 
“manufacturers bear no liability for  giving, or failing to give, accurate or  complete information to 
those vaccinated, and have only to provide relevant information to doctors, who must give patients 
CDC Vaccine Information Statements. 49” (as cited in 27).
The effectiveness and duration of this vaccine against cervical cancer  were unknown in 2006 yet 
Gardasil® was named the pharmaceutical “brand of the year” for  building a ‘market out of thin air’ 
26. In 2008 worldwide sales reached $1.4 billion 26. This was an HPV  16/18 vaccine being promoted as 
a cervical cancer vaccine to females aged 9 -26; even though it had not been tested in females under 
15 years of age 5.
Many adverse events to HPV vaccines were reported during the two and a half years following the 
licensure of the vaccine 5. The US Centers for Disease Control (CDC) and the Food and Drug 
Administration (FDA) operate the US Adverse Events Reporting System (VAERS) 5. This is a voluntary, 
national, passive surveillance system set up to monitor the adverse events to vaccines; it enables 
manufacturers, health professionals and patients to report adverse reactions 5. 
Although an analysis of the postlicensure safety surveillance data for the HPV vaccine has been 
performed, the analysis only included adverse event data from the US 5. This is despite Gardasil® 
being licensed in many foreign countries 5. The decision to use only American data was justified on 
the grounds that US data offers more complete information and is more feasible for  follow up studies 
for medical review 5. Slade et al state 70% of the adverse event reports in their  analysis came from 
the manufacturer  5. Of these reports, 90% did not provide sufficient identifying information to allow 
medical review of the individual cases 5. As a result of this failure in the system, VAERS data cannot 
be used to infer  causal associations between vaccines and adverse events 5. This also nullifies the 
stated reason for excluding adverse event data from foreign countries, as the majority of the data did 
not permit medical review. This shows an absence of rigorous surveillance and analysis of adverse 
events which is essential in determining the safety of the vaccine.    
The adverse events reported to VAERS included hypersensitivity, anaphylaxis, Guillaine-Barre 
syndrome, transverse myelitis, pancreatitis, venous thromboembolic events, seizures, deaths and 
pregnancy abnormalities 5. An accurate comparison of adverse events, including congenital 
abnormalities and spontaneous abortion after vaccination, cannot be made from the clinical trials 
because an inert placebo was not used 25. The manufacturer funded clinical trials used the adjuvant, 
aluminum, as the placebo in the unvaccinated group 25: a chemical known to be linked with serious 
adverse events 28. Therefore, the safety data provided by the clinical trials is inadequate.
In addition, adverse events were only monitored for 15 days after  the administration of the vaccine 
25. An accurate picture of the harmful events of a vaccine must be obtained from a systematic, 
prospective, long-term assessment of adverse events 5.  Since 2006 there have been 94 deaths and 
21,634 adverse events reported to VAERS 29. Of these events 4,386 have resulted in permanent 
damage 29. The VAERS statistics are believed to represent only one-tenth of the population damaged 
by the vaccine as this is a passive reporting system 5.  There has been no systematic, active, long-
term surveillance of the adverse events resulting from this vaccine since it was marketed five years 
ago. 
The evidence cited above illustrates there was no requirement for  the manufacturer  to prove this 
vaccine was safe and effective before it was marketed to women. 
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Discussion
There are many serious ethical and scientific concerns regarding the promotion of HPV  vaccines to the 
public. The lack of correlation between cervical cancer  mortality and infection with high-risk HPV sub-
types indicates that lifestyle and environmental factors play a significant role in the progression of HPV 
infection to carcinoma. HPV vaccines have been promoted to women as a cervical cancer vaccine when 
in fact they guard against only two of many HPV sub-types. They have also been promoted to women 
before the efficacy and safety profile has been established.  
Scientists used an inappropriate surrogate to determine the efficacy of HPV vaccines against cervical 
cancer. The observation of pre-cancerous lesions in an age group that rarely gets cervical cancer, and in 
which these lesions mostly clear  without leading to cervical cancer, was not an adequate measure of 
the possible reduction in cervical cancer  incidence. This is particularly the case when many other  HPV 
sub-types can infect and cause cervical cancer. There were known risk factors for this disease yet the 
clinical trials did not select the study group for these risk factors. Women have been misled by the 
claim that the vaccine is 98% effective when this result was only obtained for the study group that was 
not infected with HPV  16/18 prior to vaccination. The reality is that many women will already be 
infected with HPV 16/18, as it is a common infection, and efficacy in this group was only 44%. 
The health department admits that screening for high-risk HPV infection would identify a very large 
number of women but only a few of these are at risk of cervical cancer  7. Taking a drug to prevent 
infection from HPV 16 and 18 results in a similar situation – the majority of the women on the drug 
would not be at risk of cervical cancer. Many of the pre-cancerous lesions identified in cervical cancer 
screening and included in the incidence rates for cervical cancer, will remain sub-clinical throughout 
life and would otherwise have gone unnoticed 16. 
Vaccinating the majority of women for  an infectious disease that is mostly asymptomatic can expose 
the population to more harm than good. Screening programs are a safe and cost-effective measure of 
reducing this disease and women still need to be screened after  vaccination 7. It is time to question 
the cost-benefit of exposing women to the potential harm of a vaccine when cervical cancer was 
reduced to low levels in developed nations before a vaccine was introduced. 
Conclusion
It can be claimed that HPV infection is a necessary precursor  to most cervical cancers but if most HPV 
infections do not progress to cervical cancer then a vaccine against two strains of many high-risk HPV 
subtypes will not be beneficial to the majority of women. 
HPV vaccines have been promoted to women as a cervical cancer  vaccine without any definitive 
evidence they will prevent cervical cancer. In addition, no long-term systematic surveillance has been 
implemented to establish the safety of the vaccine over the 5 years it has been used. It is clear  that 
government policy decisions and the marketing of vaccines have not been based on the best available 
scientific evidence. This is detrimental to the health of the population and needs to be addressed in 
order to maintain trust in the institutions that are supposed to protect public health.
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Appendix 1: The Limitations of the Bosch et al, 1995 Study.
Whilst Bosch et al, 1995, claim their international study of 1000 tumors confirms the role of HPV’s as 
the central etiological factor in cervical cancer  worldwide, their  evidence does not explain why there 
is a higher  risk of cervical cancer in developing nations than developed nations. They claim that “HPV 
prevalence was remarkably homogonous among the countries’ 2. The statement that HPV’s are the 
central etiological factor  in cervical cancer  development relies upon detection methods being ‘truly 
sensitive and specific’ and ignores the epidemiological evidence that indicates co-factors are necessary 
to initiate cancer development. 
The limitations of this study are listed below: 
1. This study only included 10 of 18 regions for which cervical cancer incidence has been recorded
2. It did not include Asia and India which have very high rates of cervical cancer
3. In each country the size of the study is limited and the cases cannot be claimed to be 
representative.
4. The results alter according to the method of detection used. For example, analysis of the 66 
HPV- negative specimens using additional HPV detection methods (eg. other primers) alters the 
number of negative tumors to fewer than 5%.
5. In the final analysis HPV-negative results were only accepted from specimens with adjacent, 
confirmed tumor  tissue. ‘This was to avoid false-negative results’. However, by doing this the 
researchers were influencing the result.
6. The researchers state that their prevalence estimate of 93% maybe slightly inflated because 
the only restrictions for  HPV-positive specimens were diagnostic confirmation and PCR 
sufficiency.
7. Whilst it is stated that all HPV  detection was carried out by one expert laboratory and by one 
histological reviewer, it would be important for the results to be confirmed by another 
reviewer to ensure there is agreement. This is because there is subjectivity in the 
interpretation of the result. The study does not state that the results were checked by an 
independent researcher. 
The primary researchers involved with these studies have links to industries that profit from 
vaccines 2, 14, 3, 13.
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Appendix 2: The Strength of Evidence for HPV types in Cervical Carcinomas
Despite the significant evidence illustrating environmental and lifestyle factors are implicated in the 
etiology of this cancer, Bosch et al, stated in 1995 that epidemiological studies have shown that the 
association of genital human papillomavirus with cervical cancer is “strong, independent of other risk 
factors and consistent in several countries” 2. This contradicts all the evidence of previous 
epidemiological studies. Prior  to 1995 most scientists were claiming a multifactorial etiology for 
cervical cancer. At this time, Bosch et al, realized it was necessary to show that HPV  is present in all 
cases of cervical cancer in order  to prove that HPV is the main factor  in cancer etiology. So they set out 
to conduct an international study of HPV sub-types in invasive cervical cancer  2. The aim of this study 
was to characterize the distribution of HPV types in cervical cancer  in different geographical regions. 
They state “this is essential to the development of vaccination strategies to curb the burden of cervical 
cancer” 2. So even though HPV  was not always found in carcinomas and the geographical distribution of 
HPV sub-types had not been mapped Bosch et al, were carrying out this research with the aim of 
developing a vaccine. 
Prior to this study it was believed that HPV DNA rates in tumor specimens were about 60-90% 13.  By 
1995 it was believed that the filter  in situ hybridization technique used to identify HPV DNA in 
epidemiological studies in the eighties had inadequate specificity and sensitivity 13.  There was of 
great concern regarding the variation in laboratory methods with different levels of specificity and 
sensitivity for  detecting HPV DNA 13. Therefore a new biological technique was used in the Bosch et al 
study that was believed to be highly specific and sensitive. This was polymerase chain reaction (PCR) 
protocol based on consensus primers flanking a relative conserved region in the L1 gene of HPV  13. This 
technique is also called MY09/11 13. They concluded from their study that new molecular  biology 
techniques are ‘truly sensitive and specific’ and they believed their  result confirmed the plausibility of 
HPV infection as the pre-cursor event leading to cervical cancer 2. 
This claim has been made based upon a biological test and the IARC states case series can only provide 
suggestive results and can never serve as a basis for causal inferences 6. A claim of causality based on 
PCR tests ignores the influence of host characteristics and environmental factors that are known to 
influence pathogenesis. Bosch et al, (1995) state “more than 35 distinct HPV types are known to infect 
the genital tract complicating the detection and distinction of these agents” 2. This must be taken into 
account when assessing the reliability and specificity of the tests. 
The Bosch et al, (1995) study tested nearly 1000 tumors and the negative-HPV  tumors were re-tested 
using different methods 2. It was found that HPV DNA could be detected in “separate portions from the 
same specimen, which raised the prevalence to 93% and even higher – “to 95% on re-analysis with PCR 
using primers” 2, p.780. Franco believes that the article by Bosch et al, 1995, can be viewed as a 
critical contribution to our  understanding of the etiology of cervical cancer.  He says ‘traces of HPV 
were detected in 95% of all cervical cancers’ 13. On this basis he claims that ‘HPV  infection might turn 
out to be the first cause of a human cancer  shown to be a necessary one’- even though this evidence is 
dependent upon the detection method used and still leaves 5% of tumors without evidence of HPV 
infection 13. 
The sub-types of HPV  have been found in the following frequencies globally - HPV 16 (50%) of cases, 
HPV 18 (12%), HPV 45 (8%) and HPV 31(5%) 2. Prevalence of these types also varied geographically. 
On the evidence of the Bosch et al study, Franco questions the existence of cervical cancers that are 
induced by carcinogenic routes other than HPV  infection 13. He suggests HPV  free cancers might be 
reflecting loss of the HPV  genome as the disease progresses. This is speculation. Rather  than accepting 
that it’s possible some tumors are induced by factors other  than HPV, he suggests researchers will have 
to demonstrate that “failure to detect HPV DNA is not due to insufficient sensitivity” of the test 13. 
Franco has taken the position that an absence of HPV  genome is not because there is an absence of 
HPV genome but rather a loss due to disease progression and he is assuming the HPV was there in the 
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first place. This is interpreting the results to produce the desired outcome. It is not evidence-based 
science.  
In addition, if HPV DNA is found in organs and tissues where it is not expected to be found he claims 
“researchers will have to prove that “an occassional HPV-tissue association is not due to insufficient 
specificity or  contamination” 13. Again Franco is providing an explanation for the unexpected result to 
fit in with the desired outcome. 
Franco states earlier in his article that “an easily diagnosed viral infection as the pre-cursor event 
leading to cervical cancer calls for action on 2 fronts: 
1. primary prevention by immunisation against HPV and 
2. secondary prevention by cytology screening with testing for cervical HPV infection. 
It would appear  that the researchers were pre-empting the result in order  to find evidence to support 
the preventative measures they would like to implement: vaccination programs. 
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